Emergent BioSolutions Inc
Biotechnology
Emergent BioSolutions Inc (EBS) Stock News
The latest EBS headlines and market coverage — 3 recent stories, updated throughout the day.
- Zacks Investment Research·Neutral
Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?
Emergent Biosolutions stock jumped 14.4% following positive news including a $24 million BARDA contract for Cyfendus, a three-year Canadian government contract for Narcan nasal spray, and a $75 million debt repurchase. However, the company faces headwinds with expected quarterly losses of $0.37 per share and revenues declining 46.6% year-over-year. With unchanged earnings estimates and a Zacks Rank #3 (Hold) rating, analysts question whether the rally can sustain.
- GlobeNewswire Inc.·
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
Pomerantz LLP announced investigations into potential securities fraud at Emergent BioSolutions, Klarna Group, and Dr. Reddy's Laboratories. Emergent reported a $191.3 million impairment charge on its NARCAN asset group and cut full-year revenue guidance by 10.8%, citing increased competitive intensity. The stock fell 29.58% on the news.
- GlobeNewswire Inc.·
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBS
Pomerantz LLP is investigating potential securities fraud claims against Emergent BioSolutions following the company's August 5, 2026 earnings report. Emergent reported a $191.3 million non-cash impairment charge on its NARCAN asset group, resulting in a $180.2 million net loss, and cut full-year revenue guidance by 10.8%. The company attributed the decline to increased competitive intensity. Emergent's stock price fell 29.58% to $5.31 per share on August 6, 2026.